Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence

Chronic hepatitis C virus (HCV) infection with advanced cirrhosis or post‐liver transplantation recurrence represents a high unmet medical need with no approved therapies effective across all HCV genotypes. The open‐label ALLY‐1 study assessed the safety and efficacy of a 60‐mg once‐daily dosage of...

Descripción completa

Detalles Bibliográficos
Autores principales: Poordad, Fred, Schiff, Eugene R., Vierling, John M., Landis, Charles, Fontana, Robert J., Yang, Rong, McPhee, Fiona, Hughes, Eric A., Noviello, Stephanie, Swenson, Eugene S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Viral Hepatitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069651/
https://www.ncbi.nlm.nih.gov/pubmed/26754432
http://dx.doi.org/10.1002/hep.28446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069651/
https://www.ncbi.nlm.nih.gov/pubmed/26754432
http://dx.doi.org/10.1002/hep.28446

Ejemplares similares